With rich countries like the US finding it hard to fund gene therapies, it is worth asking whether these projects will ever reach patients in developing countries. And if…
The first sickle cell and beta thalassaemia patients have been enrolled into a Crispr/Cas9 trial, heating up a race with Bluebird, Sanofi, Sangamo and Editas.
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.
After a trial failure last week, Caladrius Biosciences has not abandoned hope for its T regulatory cell therapy in type 1 diabetes, but funding might become a problem.
Tiny signs of a therapeutic benefit are offset by safety worries, as the company pivots to higher doses and second-generation projects.
In the race to develop a haemophilia B gene therapy Uniqure now has the upper hand.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
The private UK group could steal the thunder of rivals like Spark, Uniqure and Biomarin.